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Abstract
Metastasis-associated C4.4A, which becomes upregulated during wound healing and, in some tumors, during tumor
progression, is known to be frequently associatedwith hypoxia.With the function of C4.4A still unknown, we explored
the impact of hypoxia on C4.4A expression and functional activity. Metastatic rat and human tumor lines upregulate
C4.4A expression when cultured in the presence of CoCl2. Although hypoxia-inducible factor 1α (HIF-1α) becomes
upregulated concomitantly, HIF-1α did not induce C4.4A transcription. Instead, hypoxia-induced C4.4A up-regulation
promoted in vivo and in vitro wound healing, where increased migration on the C4.4A ligands laminin-111 and -332
was observed after a transient period of pronounced binding. Increased migration was accompanied by C4.4A asso-
ciating with α6β4, MT1-MMP1, and TACE and by laminin fragmentation. Hypoxia also promoted the release of C4.4A
in exosomes and TACE-mediated C4.4A shedding. The association of C4.4A with α6β4 and MT1-MMP1 was main-
tained in exosomes and exosomal α6β4- and MT1-MMP1–associated C4.4A but not shed C4.4A sufficient for laminin
degradation. Hypoxia-induced recruitment of α6β4 toward raft-located C4.4A, MT1-MMP, and TACE allows for a shift
from adhesion to motility, which is supported by laminin degradation. These findings provide the first explanation for
the C4.4A contribution to wound healing and metastasis.
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Introduction
C4.4A is a glycosyl-phosphatidyl-inositol–anchored molecule and
belongs, like the urokinase-type plasminogen activator receptor
(uPAR), to the Ly6 family [1–3]. C4.4A shares with uPAR three-
finger protein domains, characterized by three to six S -S bridges,
which guarantee maintenance of domain structure by stabilizing the
hydrophobic nucleus of the protein [4,5]. uPAR has three and
C4.4A two strongly hydrophobic three-finger protein domain [6].
C4.4A has 5 to 6 N -glycosylation sites close to the second TFP do-
main and 15 O-glycosylation sites in a Ser/Thr–rich region at the
C-terminus [7]. C4.4A associates with laminins (LN) 111 and 332
(formerly LN1 and LN5) and galectin-3 [8].
C4.4A expression is restricted to the basal and suprabasal layers
of squamous epithelium in nontransformed tissue [1,2,7,9,10],
where it becomes upregulated during wound healing [7,10]. High
C4.4A expression has been seen in several types of carcinoma like
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mammary, renal cell, colorectal [11–13] and most pronounced non–
small cell lung cancer [14]. Its expression in other types of cancer, like
esophageal cancer becomes regulated during tumor progression
[15,16]. C4.4A transcription requires C/EBPβ and is enhanced by
JunD or c-Jun [17], which fits to upregulated expression during
wound healing [18–22].
We here aimed to shed light on the molecular mechanism of C4.4A
activities, which remain elusive, despite C4.4A being consistently asso-
ciated with tumor progression and wound healing [3]. These two ac-
tivities of C4.4A are frequently associated with hypoxia [23,24], which
initiates a gene transcription program frequently through hypoxia-
inducible factor (HIF) [25,26]. Stabilized HIF-1α undergoes nuclear
translocation and associates with transcriptional coactivators [27,28].
Because the C4.4A promoter contains three potential HIF-1α response
elements (HREs), we first evaluated whether hypoxia-induced HIF-1α
may contribute to C4.4A transcription and whether hypoxia influences
C4.4A activity in wound healing and tumor cell migration. Under
hypoxia, C4.4A forms a complex with α6β4 and MMP14 (formerly




The rat tumor lines were BSp73ASML (ASML, C4.4A+, α6β4
+,
metastasizing), BSp73AS (AS, C4.4−, α6β4
−, nonmetastasizing) [29],
and BSp73AS1B1 (AS1B1, C4.4A cDNA-transfected AS clone,
C4.4A+, α6β4
−). The coding sequence of the C4.4A cDNA has
been cloned into the pcDNA3 vector with a CMV promoter to drive
C4.4A transcription [1]; Progressor (Prog) (C4.4A+ α6β4
+) [30], 804G
(LN332 secreting) [31], and the human A431 (LN332 secreting) [32]
were maintained in RPMI/10% fetal calf serum (FCS). The human
pancreatic cancer lines Capan-2 (metastasizing) [33], Colo357 (metas-
tasizing) [34], 8.18 (weakly metastasizing) (Tumor Bank, German
Cancer Research Center, Heidelberg, Germany; personal observations),
and BxPC3 (nonmetastasizing) [35] were maintained in RPMI/10%
FCS/10 mM Na-pyruvate. Confluent cultures were trypsinized and
split. Where indicated, cells were treated with 100 to 200 μM CoCl2
for 6 to 24 hours or maintained at 1% O2 for 6 to 12 hours.
Antibodies, Matrix Proteins, and Inhibitors
Antibodies, matrix proteins, and inhibitors are listed in Table W1.
Vesicle Depletion and Exosome Preparation
Cells were cultured (48 hours) in serum-free medium. Cleared super-
natants (2 × 10 minutes at 500g, 1 × 20 minutes at 2000g, 1 × 30 min-
utes at 10,000g) were centrifuged (90 minutes at 100,000g) and washed
(phosphate-buffered saline, 90 minutes at 100,000g). The supernatant
was collected as vesicle-depleted fraction. The pellet (crude exosomes)
was suspended in 2.5 M sucrose, overlaid by a continuous sucrose
gradient (0.25-2 M), and centrifuged (15 hours at 150,000g).
Flow Cytometry
Flow cytometry followed routine procedures. For intracellular stain-
ing, cells were fixed and permeabilized. For chloramphenicol acetyl-
transferase (CAT) assay standardization, cells were cotransfected with
the EGFP-C1 plasmid to evaluate transfection efficacy. Cells were
analyzed in a FACScan using the Cell Quest analysis program.
Reverse Transcription–Polymerase Chain Reaction
Total RNA preparation followed standard procedures. Primers are
listed in Table W2.
C4.4A Promoter Constructs, Mutations, Transfection, and
CAT Assay
A 588-bp and a 1.9-kbp C4.4A promoter constructs have been
used [17]. Three CGTG HRE sequences of C4.4A at −673 bp
(HRE1), −1183 bp (HRE2), and −1557 bp (HRE3) are shown in
Table W3. C4.4A sequences were inserted in promoterless pBLCAT3-
Basis (pBLCATB3), which contains the CAT gene [36]. Tk promoter-
containing pBLCAT2 served as control [37]. Transfection (3 μg of
pBLCAT3-C4.4A, 1 μg of EGFP-C1 or 1.75 μg of pBLCAT3-C4.4A,
1.25 μg of p(HA) HIF-1α 401Δ603 [HIF-1α with oxygen-dependent
degradation domain deletion], 1 μg of EGFP-C1) was done as described
[17]. For the CAT assay [38], lysates were standardized for protein con-
tent and transfection efficacy. Thin-layer chromatography was quan-
titated using BAS-1800II PhosphorImager (Fuji, Dusseldorf, Germany).
Immunoprecipitation, SDS-PAGE, and Western blot
Cell lysates (60 minutes, 4°C, HEPES buffer, 1% Brij96, protease
inhibitor cocktail) were centrifuged (13,000g for 10 minutes at 4°C),
incubated with antibody (overnight), and precipitated with ProteinG
Sepharose (1 hour at 4°C). Washed immune complexes were dis-
solved in Laemmli buffer. Precipitates/lysates were resolved on 10%
SDS-PAGE. Proteins were transferred to nitrocellulose membranes
(30 V for 12 hours at 4°C); membranes were blocked, blotted with
primary and HRP-conjugated secondary antibodies (1 hour at room
temperature), and developed with the ECL kit or were stained with
Coomassie blue.
Immunofluorescence and Immunohistochemistry
Cells seeded on bovine serum albumin (BSA)–, LN111-, LN332-, or
fibronectin (FN)-coated cover slides were fixed; permeabilized; blocked;
incubated with primary antibody (60 minutes at 4°C); fluorochrome-
conjugated secondary antibody (60 minutes at 4°C); blocked, incubated
with a second, dye-labeled primary antibody (60 minutes at 4°C); and
washed. Where indicated, cells were removed by EDTA. Cover slides
were mounted in Elvanol (Sigma Aldrich, Steinheim, Germany).
Shock-frozen skin sections (7 μm) were exposed to primary antibody,
biotinylated secondary antibody, and alkaline phosphatase-conjugated
avidin-biotin complex solutions. Sections were counter stained with
hematoxylin and eosin. Digitized images were generated using a Leica
DMRBEmicroscope (Leica,Wetzlar, Germany), a SPOTCCD camera,
and Software SPOT2.1.2 (Sterling Heights, MI).
Adhesion and Migration Assays
Adhesion to coated 96-well plates was determined after 30 and
240 minutes (37°C). Nonadherent cells were removed by washing.
Migration was evaluated in Boyden chambers seeding cells in the upper
chamber (RPMI/1% BSA) with/without CoCl2 and/or protease in-
hibitors. The lower chamber, separated by an 8-μm pore size poly-
carbonate membrane, contained RPMI/1% BSA or LN332 (804G
supernatant). In both assays, cells were stained with crystal violet,
measuring OD595nm after lysis. Adhesion/migration is presented as
percentage input cells. For in vitro wound healing, a subconfluent
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monolayer was scratched. Wound closure (light microscopy) is pre-
sented as percentage reduction of the freshly wounded area.
Rats and Treatment
A 1-cm-diameter full-thickness skin area was excised from the shaved
back of 8-week-old BDX rats. At the time of excision, after 4 and
7 days, rats received 100 μg of control IgG or C4.4 in 100 μl of
phosphate-buffered saline, perilesionally. Sterile gauze covering the
wound was fixed with a whole-body bandage. A 1.5-cm-diameter area,
including the wound, excised immediately, after 1, 3, 7, and 10 days,
was shock frozen. Animal experiments were government approved
(Baden-Wuerttemberg).
Statistics
Values represent the mean ± SD of triplicates and/or three repeti-
tions. P < .05 (Student’s t test) was considered statistically significant.
Results
Hypoxia-Induced C4.4A Up-regulation
The impact of hypoxia on C4.4A expression was evaluated in two
metastatic C4.4A+ rat tumor lines Prog and ASML, in AS1B1 cells
(C4.4A cDNA-transfected AS cells) [1,29], and in human pancreatic
tumor lines.
Cells were cultured in the presence of CoCl2, which mimics hypoxic
conditions [39]. High C4.4A expression in ASML and Prog cells was
increased after 6 hours of 200 μM CoCl2 treatment and increased
further during a 12-hour culture period. Culturing in 1% O2 exerted
similar effects (data not shown). AS1B1 cells showed a minor insig-
nificant increase only after 12 hours of CoCl2 treatment. AS cells re-
mained C4.4A− (Figure 1, A and B). Two human pancreatic cancer cell
lines, Colo357 and Capan-2, which express C4.4A at a medium to low
level, responded to CoCl2 treatment with a dose- and time-dependent
increase in C4.4A expression, where a subfraction showed a very high
expression after 200 μM CoCl2 treatment. 8.18 cells, which do not
express C4.4A, revealed very weak expression in approximately 15%
of cells after 12 hours of 200 μM CoCl2 treatment. BxPC3 cells re-
mained C4.4A− (Figure 1, C and 1D). Thus, hypoxia can contribute
to C4.4A protein up-regulation.
HIF-1α Does Not Promote C4.4A Transcription
Under hypoxia, stabilized HIF-1α acts as a transcription factor.
Under normoxia, AS, AS1B1, and ASML cells express HIF-1α at a
low level. In ASML cells, HIF-1α showed a strong, dose-dependent
Figure 1. Hypoxia-induced C4.4A up-regulation: (A, B) ASML, Prog, AS, and AS1B1 cells and (C, D) the human pancreatic cancer lines
Capan-2, Colo357, BxPC3, and 8.18 were cultured in the presence of titrated amounts of CoCl2 for 6 to 24 hours. (A, C) Expression of
C4.4A was evaluated by flow cytometry. Representative examples and (A) mean values of intensity of C4.4A expression or (C) the mean
percentage of stained cells and mean intensity in three different experiments is shown. CD44 expression served as control. *Significant
differences due to CoCl2 treatment. (B, D) Lysates of untreated and CoCl2-treated cells were separated by SDS-PAGE, transferred and
blotted with anti-C4.4A. Actin served as control. In rat and human tumor lines, C4.4A expression increases under hypoxia. C4.4A expression
is not or is very weakly induced by hypoxia in cell lines that do not express C4.4A in normoxia.
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increase after 12 hours of CoCl2 treatment. Up-regulation was weak
after 6 hours and declined beyond 12 hours. An increase in HIF-1α
was also seen in CoCl2-treated Capan-2 and BxPC3 cells (Figure 2A).
Notably, the latter do not express C4.4A after CoCl2 treatment. This
finding suggests that HIF-1α, if at all, may only act as a cotranscription
factor for C4.4A.
The C4.4A promoter containing three HREs at −673, −1183, and
−1557 bp (Table W3), we controlled for HIF-1α cotranscription factor
activity in hypoxia. However, when the C4.4A promoter from −588
(no HRE) or from −1957 to −1 bp were inserted into promoterless
pBLCAT3, CAT activity of transfected ASML cells, cultured under
hypoxia, was not significantly changed (Figure 2B). Furthermore,
only a slight increase in CAT activity was observed on cotransfection
with pCDNA3-HIF-1α, irrespective of whether the promoter construct
contained (1957 bp) or did not contain (588 bp) the three HRE
(Figure 2C).
Thus, hypoxia-induced C4.4A protein up-regulation does, at least,
not predominantly proceed at the transcription level.
Hypoxia-Induced C4.4A Up-regulation, LN332 Adhesion,
Keratinocyte Migration, and Tumor Cell Motility
Keratinocytes express C4.4A and C4.4A is engaged in wound re-
pair [3,7,8]. Controlling for C4.4A expression and the impact of
anti-C4.4A (C4.4) on wound repair after full-thickness skin excision
revealed a strong C4.4A expression at the leading front of migrat-
ing keratinocytes, and wound closure was strongly delayed in C4.4-
treated rats (Figure 3).
With wound repair frequently being associated with hypoxia, we
next asked whether hypoxia-induced C4.4A up-regulation affects
adhesion or migration on LN332, which, in humans and rats, is a
major C4.4A ligand [1,8,10].
ASML, Prog, AS, and AS1B1 cells adhere better to LN332 than
BSA. In addition, after 30 minutes, significantly more CoCl2-treated
than untreated ASML, Prog, and AS1B1, but not AS cells, adhere to
LN332 (Figure 4A). We also evaluated binding to collagen I, III, and
IV as well as to FN and vitronectin. Binding did not differ between
AS and AS1B1 cells (data not shown), which is in line with the re-
sults of pull-down assays that revealed LN332 and (weakly) LN111,
but not other matrix, proteins to bind to recombinant C4.4A [8].
Because the increase in binding was more pronounced in ASML
and Prog, which both, and distinct to AS, express α6β4, we next asked
for the contribution of C4.4A versus α6β4 [40] to LN332 adhesion.
C4.4 and B5.5 (anti-α6β4) inhibited LN332 binding of untreated
and CoCl2-treated ASML and Prog cells with equal efficacy, and no
additive inhibitory effect was seen in the presence of both antibodies
(data not shown). Binding of CoCl2-treated ASML and Prog cells, but
not of AS and AS1B1 cells to BSA, was also slightly inhibited by C4.4
and B5.5, which may be a consequence of both these lines, distinct to
AS cells, secreting LN332 [44] (unpublished observations). Binding of
AS1B1 cells was only inhibited by C4.4 (Figure 4B).
Because inhibition by C4.4 and B5.5 was stronger in CoCl2-treated
cells, we speculated that stress could support joint C4.4A-α6β4 ac-
tivities. C4.4A and α6β4 did not colocalize in ASML and hardly in Prog
cells, when seeded on BSA-coated plates. Weak colocalization was seen
in the presence of CoCl2 or on LN332-coated plates. Instead, C4.4A
and α6β4 strongly colocalized in CoCl2-treated ASML and Prog cells
seeded on LN332 (Figure 4C ) and hypoxia strengthened C4.4A-
α6β4 coimmunoprecipitation (Figure 4D).
C4.4A-mediated LN332 binding is transient and could be restored in
the presence of a protease inhibitor [1]. This also accounts for CoCl2-
treated ASML and Prog cells. After 4 hours, adhesion to LN332 did
not consistently exceed adhesion to BSA and the adhesion supporting
effect of CoCl2 treatment was weak or abolished. Adhesion of CoCl2-
treated ASML and Prog cells was partly restored in the presence of broad
serine protease (aprotinin) and MMP (MMP-Inh.II) inhibitors. In-
stead, in C4.4A−, α6β4
− AS cells’ adhesion to LN332 was stronger after
4 hours than after 30 minutes. Adhesion was not influenced by CoCl2
and remained unaltered in the presence of MMP-Inh.II. In AS1B1 cells,
slightly reduced adhesion to LN332 was at a borderline significant level
restored by MMP-Inh.II only in CoCl2-treated cells (Figure 5A). This
indicated an essential contribution ofC4.4A to reducedLN332 adhesion,
which becomes strengthened by α6β4.
As LN332 adhesion decreased with time, hypoxia enhanced migra-
tion of ASML and Prog cells on LN332 as revealed by in vitro wound
healing. Both C4.4 and B5.5 inhibited wound closure of ASML and
Figure 2. HIF-1α does not promote C4.4A transcription: (A) ASML,
Capan-2, and BxPC3 cells were cultured in the presence of 200 μM
CoCl2 for 6 to 24 hours. HIF-1α expression was evaluated by WB;
actin served as control. (B, C) The −1- to −588-bp sequence (no
HRE) and the−1- to −1957-bp C4.4A promoter region (three HREs)
were cloned into the pBLCAT3 vector. The pcDNA3.1CAT vector
(CMV promoter) served as positive; the promoterless pBLCAT3
vector, as negative control. ASML cells were cotransfected with
the EGFP-C1 plasmid for standardization. Cells were cultured in the
presence or absence of 200 μM CoCl2 for 16 hours. (B) Impact of
CoCl2. (C) Impact of HIF-1α as revealed by cotransfection. CAT ac-
tivity was quantified using a PhosphorImager system. Relative CAT
activity (mean ± SD of three experiments) is shown. No significant
differences have been seen. Upregulated C4.4A expression under
hypoxia may not rely on HIF-1α–induced C4.4A transcription.
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Prog cells on LN332-coated plates in the presence or absence of CoCl2
(Figure 5B). In line with the MMP-Inh.II–restored adhesiveness to
LN332, MMP-Inh.II interfered with migration. MMP-Inh.II exerted
no or a minor effect on wound healing of Prog and ASML cells on
BSA but significantly inhibited wound healing on LN332 in the pres-
ence of CoCl2 (Figure 5C).
Hypoxia-induced increased migratory activity also accounted for
transwell migration of ASML and Prog cells, which was promoted
by CoCl2 treatment and inhibited by C4.4 and B5.5 (Figure 5D).
Transwell migration toward LN332 was inhibited by MMP-Inh.II,
although the effect was weak for Prog cells (Figure 5E ).
Taken together, hypoxia supports an association of the two LN332
receptors C4.4A and α6β4. Both molecules promote short-term LN332
adhesion but lasting migration. An MMP inhibitor restores adhesive-
ness and interferes with migration. Thus, hypoxia might be accompa-
nied by increased protease activity accounting for LN332 degradation,
where LN332 degradation products can exert chemotactic activity
[41–43]. Alternatively, hypoxia might contribute to C4.4A shedding
or release.
C4.4A Cooperation with Proteases
ASML [44] and Prog cells secrete LN332. C4.4A poorly colocalized
with LN332 on BSA-coated plates under normoxic conditions. Co-
localization was promoted when CoCl2-treated cells were seeded on
LN332-coated plates (Figure 6A). Because the experimental setting
did not allow to judge on LN332 degradation, ASML and Prog cells
were seeded in the presence or absence of CoCl2 on uncoated plates,
removing cells after 2 days of culture by EDTA and staining for
LN111, LN332, and FN. In CoCl2-treated cultures, the rim staining
for LN332 was stronger and more focalized, but the area below the
cell body was free of LN332. Instead, FN remained deposited below
the cell body independent of CoCl2 treatment. LN111 deposition
was reduced but not abolished. Staining of cell-free areas confirmed
poor LN332, high FN, and intermediate LN111 recovery (Figure 6B).
These findings argued for LN332 and (partial) LN111 fragmenta-
tion. To control the hypothesis, LN111 and LN332 (804G super-
natant) were cocultured for 24 hours with ASML cells in the presence
of CoCl2 with/without MMP-Inh.II. Cells were removed, and the LNs
were separated by SDS-PAGE. Gels were stained with Coomassie blue
or proteins were transferred and blottedwith anti-LN111 or anti-LNγ2.
Coomassie blue staining provided evidence for LN111 and LN332
fragmentation, which was reduced when cultures contained MMP-
Inh.II. Western blot (WB) confirmed LNγ2 degradation, and a weaker
LN111 band was recovered when LN111 was cocultured with CoCl2-
treated ASML cells but not when cultures contained MMP-Inh.II
(Figure 6C).
Figure 3. Keratinocyte migration during wound healing and C4.4A expression: The back skin of BDX rats was wounded by a 1-cm-
diameter full-thickness skin excision. Rats received at days 0, 4, and 7 after wounding a perilesional injection of 100 μg of control
IgG or C4.4. (A) At the time of wounding, after 1, 3, 7, and 10 days, a 1.5-cm area around the wound was excised and shock frozen.
Sections (7 μm) were stained with C4.4 or mouse IgG1 (control) and Mayer hematoxylin. Scale bar, 100 μm. Photographs from the
wounded skin were obtained from the left side of the wound border. Arrows indicate the migration front of keratinocytes. (B) The mean
diameter ± SD (five rats per group) of the wound area is shown. *Significant differences between control IgG and C4.4-treated wounds.
Skin wound healing is accompanied by a high C4.4A expression. C4.4 retards keratinocyte migration.
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Figure 4. The impact of hypoxia and upregulated C4.4A expression on LN332 adhesion. (A, B) Untreated and CoCl2-treated ASML, Prog,
AS, and AS1B1 cells were seeded on BSA- or 804G supernatant (LN332)–coated plates and cultured for 30 minutes with or without
CoCl2. (B) Cultures contained in addition C4.4 or B5.5 (10 μg/ml). (A, B) The percentage of adherent cells (mean ± SD of triplicates) is
shown. (A) *Significant differences between BSA and LN5. sSignificant difference of untreated versus CoCl2-treated cells. (B) *Signifi-
cant antibody inhibition. (C) ASML and Prog cells were cultured on 804G supernatant (LN332)–coated cover slides with or without CoCl2.
Fixed cells were stained with B5.5/anti-mouse IgG-Cy2 and, after blocking, with C4.4-TxR. Single fluorescence staining and digital over-
lays are shown. Scale bar, 10 μm. (D) ASML cells were cultured for 16 hours with or without CoCl2. Lysates were immunoprecipitated
with B5.5. After SDS-PAGE and protein transfer, membranes were blotted with C4.4 and anti-β4. Hypoxia increases LN332 adhesion,
which is equally well inhibited by C4.4 and B5.5, indicating that LN332 adhesion might pursue by a C4.4A-α6β4 complex, which is in line
with the colocalization and coimmunoprecipitation of the two molecules.
Figure 5. The impact of protease inhibitors on adhesion to and migration on LN332: (A) Untreated and CoCl2-treated ASML and Prog
cells were seeded on BSA- or 804G supernatant (LN332)–coated plates. Where indicated, cultures contained CoCl2 and/or aprotinin or
MMP-Inh.II. Adhesion was measured after 4 hours. The percentage of adherent cells (mean ± SD of triplicates) is shown. (B, C) Sub-
confluent monolayers of ASML and Prog cells on BSA- or 804G supernatant (LN332)–coated plates were scratched, and wound closure
was controlled in the presence or absence of CoCl2 for 48 or 72 hours. In C, cultures contained MMP-Inh.II. Wound closure was con-
trolled using an inverted microscope. Representative images (B and C: scale bar, 50 μm) and the mean ± SD (triplicates) of wound
closure are shown. (D, E) Cells were seeded in Boyden chambers, the lower chamber contained RPMI/1% BSA or 804G supernatant
(LN332). (D) Cells were preincubated with C4.4, B5.5, or mouse IgG1. (E) Cultures contained DMSO or MMP-Inh.II. Migration was evalu-
ated after 16 hours. The mean ± SD (triplicates) of transwell migrating cells is shown. (A-D) *Significant differences between BSA and
804G supernatant (LN332). sSignificant difference of untreated versus CoCl2-treated cells. For antibody (B, D) and MMP-Inh.II inhibition
(A, C, E), P values are shown. Hypoxia-only transiently increases LN332 adhesion but strongly promotes migration of C4.4A+ cells on
LN332, which can be inhibited by C4.4, B5.5, and MMP-Inh.II. This suggests, besides an involvement of the C4.4A-α6β4 complex in
adhesion/migration, provision of a migratory stimulus by LN332 fragmentation.
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Thus, C4.4A might promote motility through associated proteases
involved in LN degradation. According to the inhibitory activity of
MMP-Inh.II, MMP14 was considered a possible candidate. Weak co-
localization of MMP14 with C4.4A and α6β4 in resting cells became
strong when CoCl2-treated cells were grown on LN332-coated slides
(Figure 7A), which corresponded to an increase in coimmunoprecipita-
tion of C4.4A and α6β4 with MMP14 in CoCl2-treated ASML cells.
C4.4A and more pronounced α6β4 also coimmunoprecipitated TACE,
but not uPA, uPAR, MMP2, and MMP9. Although the C4.4A
and α6β4 association with TACE was CoCl2 treatment independent,
TACE clustering was more pronounced in CoCl2-treated ASML cells
(Figure 7, B-D).
The association of C4.4A with TACE, possibly through α6β4, and
the fact that C4.4A has a highly sensitive cleavage site [45] and is
delivered in exosomes [8] prompted us to evaluate whether CoCl2 treat-
ment supports C4.4A cleavage and/or exosomal release. C4.4A is recov-
ered in exosomes, a higher amount being recovered from CoCl2-treated
cells. Shed C4.4A is only recovered in the supernatant of CoCl2-treated
ASML cells. C4.4A shedding is largely abolished in the presence of the
TACE inhibitor (TAPI). However, TAPI did not influence the delivery
in exosomes. Exosomal C4.4A and α6β4 also coimmunoprecipitate
with MMP14 and TACE (Figure 7E).
These findings raised the question whether exosomal or shed C4.4A
would contribute to LN degradation. When exosomes and supernatant
from CoCl2-treated ASML cells were coincubated with LN111 and
LN332, exosomes, but not shed C4.4A, partly degraded LN111 and
LN332. LN degradation by exosomes was also inhibited by MMP-
Inh.II (Figure 7F). The experiment was repeated with hLN332, which
confirmed partial degradation by Colo357-derived exosomes and in-
hibition of degradation by MMP-Inh.II. Blot analysis with anti-LNα3,
-β3, and -γ2 provided evidence for partial degradation of all three
LN332 chains (Figure 7G).
Taken together, hypoxia strengthens C4.4A expression and promotes
migration on LN111 and LN332. Migration is accompanied by α6β4
and MMP14 recruitment toward C4.4A and focalized LN5 fragmenta-
tion. Owing to the high recovery of C4.4A- and α6β4-associatedMMP14
in exosomes, the process of focalized LN332 degradation can also proceed
in the surrounding tissue.
Figure 6. Cooperation of C4.4A and MMP14 in LN332 degradation. (A) ASML and Prog cells cultured on 804G supernatant (LN332)–coated
cover slides with or without CoCl2 were fixed and stained with anti-LNγ2/anti–mouse-Cy2 and C4.4-TxR. Single fluorescence and digital
overlays are shown. (B) ASML and Prog cells were cultured with or without CoCl2 on glass slides. Cells, cell ghosts (EDTA), and areas,
where cells apparently were removed completely (“cell-free” area), were stained with anti-LNγ2, anti-LN111, anti-FN, and Cy3-labeled sec-
ondary antibodies. Single fluorescence staining is shown. Scale bar, 5 μm. (C) ASML cells were suspended in 25 μg of LN111 or 250 μg
of 804G supernatant (LN332). Cells were incubated at 37°C for 16 hours in the presence of CoCl2 with or without MMP-Inh.II. Cells were
removed, and supernatants were dried, dissolved in lysis buffer, and separated by SDS-PAGE. Gels were stained with Coomassie blue or,
after transfer, blotted with anti-rat LN111 or anti-rat LNγ2. Hypoxia strengthens C4.4A colocalization with LN332 and supports LN111 and
LN332 but not FN fragmentation. MMP-Inh.II inhibits LN degradation.
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Discussion
The function of metastasis-associated C4.4A, with very restricted ex-
pression in normal tissue [1,2,7,9,10], remains elusive [3]. We here
report that hypoxia-induced C4.4A up-regulation promotes transi-
tion from a sessile toward a mobile phenotype through associating
with α6β4 and proteases, which supports focalized matrix degrada-
tion. The process is strengthened by the release of C4.4A, α6β4,
and MMP14 into exosomes.
Regulation of C4.4A Expression in Hypoxia
Low oxygen and, as a surrogate, CoCl2 treatment [39] are accompa-
nied by HIF-1α transport to the nucleus, where it acts as a transcription
Figure 7. The C4.4A association with proteases, C4.4A shedding, and exosome inclusion in hypoxia. (A) ASML and Prog, grown on BSA- or
804G supernatant (LN332)–coated plates in the presence or absence of CoCl2, were stained with anti–MMP14/anti–rabbit-Cy2 and C4.4-TxR
or B5.5-TxR. Digital overlays are presented. Scale bar, 5 μm. (B) Expression of C4.4A, α6β4, uPA, uPAR, TACE, MMP2, MMP9, and MMP14
in untreated and CoCl2-treated ASML cells. (C) Coimmunoprecipitation of C4.4A and α6β4 with uPAR, TACE, MMP2, MMP9, and MMP14.
(D) Colocalization of C4.4A and α6β4 with TACE in untreated and CoCl2-treated ASML and Prog grown on 804G supernatant (LN332)–coated
glass slides. Digital overlays of staining with anti–TACE/anti–rabbit-Cy2 and C4.4-TxR or B5.5-TxR are shown. Scale bar, 5 μm. (E) ASML cells
were cultured in the absence of FCS with or without CoCl2 and TAPI. Vesicle-depleted supernatant and lysed exosomes (20 μg) were sepa-
rated by SDS-PAGE, transferred, and blotted with C4.4, anti-MMP14, and anti-TACE. Precipitates of exosome lysates with C4.4 and B5.5
were separated by SDS-PAGE and, after transfer, blotted with C4.4, anti-MMP14, and anti-TACE. (F, G) Vesicle-depleted supernatant or
exosomes of CoCl2-treated ASML and Colo357 cells were incubated with 10 μg/ml LN111 or 50 μg of 804G supernatant (LN332) or
50 μg of A431 supernatant (LN332) in the presence or absence of MMP-Inh.II. After 16 hours of incubation, cultures were dried and pro-
teins were dissolved in lysis buffer. Samples were separated by SDS-PAGE, and gels were stained with Coomassie blue or proteins were
transferred and stained with anti-rat LN111, anti-rat LNγ2, anti-human LNα3, anti-human LNβ3, or anti-human LNγ2. C4.4A and α6β4 asso-
ciate with TACE and MMP14. The latter is promoted by CoCl2 treatment. Only supernatant of CoCl2-treated ASML cells contained shed
C4.4A, where TACE contributes to C4.4A shedding. Hypoxia strengthens incorporation of functionally active and associated C4.4A, α6β4,
and MMP14 into exosomes, such that LN111 and LN332 become partially degraded by exosomes.
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factor for multiple genes [26,28]. Because hypoxia is accompanied by
upregulated C4.4A expression and the C4.4A promoter contains three
HREs, we considered the possibility that HIF-1α may contribute to
C4.4A transcription. However, cotransfection with HIF-1α did not
show an HIF-1α contribution to C4.4A transcription. C/EBPβ, essen-
tially required for C4.4A transcription [17], has also been associated
with metastasis-associated gene transcription [46], gene expression in
differentiating keratinocytes, and wound repair [47,48]. However,
although a high CAT activity was observed after cotransfection with
C/EBPβ, we did not observe a further increase by CoCl2 treatment
(data not shown). Thus, high C4.4A expression under hypoxia may
be a consequence of protein stabilization. The finding that CoCl2 treat-
ment did not induce expression in C4.4A-negative tumor lines is in line
with this interpretation.
Cooperation of C4.4A with α6β4 and MMP14
C4.4A is strongly expressed in migrating keratinocytes during
wound repair where a direct contribution to keratinocyte migration
has been demonstrated by C4.4, significantly inhibiting wound heal-
ing. In vitro, CoCl2 treatment promoted migration of C4.4A
+ tumor
cells on LN332, a major C4.4A ligand [8], after a transient increase
in LN332 adhesion.
The engagement of C4.4A in the shift toward motility on LN332
could rely on hypoxia-induced associations of C4.4A with α6β4 and
MMP14. On LN332, but not on BSA, C4.4A colocalizes and asso-
ciates with α6β4, with focalized colocalization and association being
stronger under hypoxia. ASML, Prog, and AS/AS1B1 also express α3β1
and α6β1. However, neither of these integrins coimmunoprecipitated
C4.4A in resting cells or in stimulated cells. Thus, it is the association
between C4.4A and α6β4 that has bearing on adhesion/migration of
ASML and Prog cells. LN332 is a major ligand for α6β4 [40,49], and
one could have speculated that C4.4A only acts as an accessory molecule.
This has been excluded because recombinant C4.4A binds LN332 [8]
andAS1B1 cells, which do not expressα6β4 [1], also showing pronounced
LN332 binding. However, the effect of C4.4A by itself as demonstrated
in AS1B1 cells on LN332 binding andmotility (data not shown) is much
weaker than in cells, where C4.4A associates with α6β4 in hypoxia
(ASML, Prog). In line with this finding, adhesion and migration on
LN332 became equally well inhibited by C4.4 and anti-α6β4.
Pronounced adhesion of ASML and Prog cells to LN332 is transient.
It is known that α6β4 contributes to tumor cell motility [49–54] that
can be initiated through binding of α6β4 to LN332. Furthermore,
α6β4 becomes recruited toward rafts in stimulatory conditions [55,56].
This is accompanied by phosphorylation of the β4 cytoplasmic domain
[57–59], recruitment of Shc, and activation of downstream signaling
Figure 8. Schematic presentation of C4.4A, α6β4, and protease cooperation in LN migration. (A) C4.4A, MMP14, and TACE are raft located
molecules. In resting cells, α6β4 is located outside rafts. Both C4.4A and α6β4 are LN receptors. (B) By binding to LN332 and supported by
hypoxia, α6β4 becomes activated and possibly through the joint LN ligand with C4.4A recruited into rafts. Within rafts, activated β4 initiates
rac activation and thereby motility and C4.4A- and α6β4-associated MMP14 becomes activated and contributes to LN degradation. In addi-
tion, C4.4A becomes cleaved by TACE. (C) Defined LN5 degradation products can act as chemoattractant, which further supports motility.
Whether shed C4.4A competes for LN binding has not been explored. (D) In activated cells, raft-located proteins are prone for internalization
and, after recruitment into multivesicular bodies, for release in exosomes. Accordingly, C4.4A- and α6β4-associated MMP14 are recovered
in exosomes, such that exosomalMMP14 further contributes to LN degradation. C4.4A is also recovered in vesicle-free culture supernatant,
which is due to C4.4A cleavage by TACE.
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molecules [60] like rac with a central role in directional cell migration
[61,62]. Taking this into account, it becomes likely that the joint activity
of C4.4A with α6β4 accounts for the shift from adhesion to motility.
Whether C4.4A actively recruits α6β4 or whether α6β4 and C4.4A come
into vicinity through their joint ligand(s) remains to be explored.
Finally, proteolytic processing of LN332 also can support cell migra-
tion [63]. The rat γ2 chain can be cleaved by MMP2 and MMP14
[42]. One of the γ2 fragments interacts with and activates the epider-
mal growth factor receptor [64]. Different LN332 fragments from the
γ2 and the α3 chain also account for the deposition into the matrix
underlying cultured cells [65,66]. MMP14 and hepsin can also cleave
the β3 chain [43,67], where hepsin cleavage promotes motility on
LN332 [67]; the α3 chain can be cleaved by several proteases includ-
ing plasmin [68]. Three observations are in line with hypoxia-induced
C4.4A up-regulation and the association with α6β4 accounting for the
pronounced migration due to LN332 fragmentation: 1) broad serine or
MMP inhibitors promoted LN332 adhesion, 2) LN332 deposits were
not recovered in CoCl2-treated cultures, and 3) an MMP inhibitor–
reduced migration on LN332. Because aprotinin partially restored
adhesion to LN332, but MMP-Inh.II exerted stronger effects on cell
migration, we tested several proteases for associating with C4.4A and
α6β4. Both LN332 ligands do not associate with uPAR, uPA, MMP2,
or MMP9 but associate with TACE and more strongly in hypoxia with
MMP14. In addition, rat and human LN332 becomes degraded by
CoCl2-treated C4.4A
+ and α6β4
+ tumor cells, and a broad MMP in-
hibitor interferes with degradation. Whether additional proteases like
hepsin may also associate with C4.4A and contribute to LN332 degra-
dation [67] remains to be explored.
Thus, the engagement of C4.4A in tissue remodeling, wound repair,
and tumor progression may well rely on its hypoxia-induced association
with α6β4 and MMP14.
Hypoxia and C4.4A Release
C4.4A shedding and exosomal release [11] are both stimulated by
hypoxia. The increase in soluble C4.4A could be linked to TACE that
cleaves C4.4A [69]. Using SILAC (stable isotope labeling by amino
acids in cell culture), the authors demonstrate in a human mammary
carcinoma line that C4.4A is a new substrate for both ADAM10 and
ADAM17/TACE and speculate that cleavage of C4.4A by ADAM10
and TACE may contribute to tumor progression [69]. Our findings
of coimmunoprecipitation of C4.4A and α6β4 with TACE, the in-
creased recovery of C4.4A in vesicle-free culture supernatant, and the
inhibition of C4.4A release by TAPI are fully in line with the described
findings and support the authors’ interpretation that the C4.4A-TACE
association may contribute to metastasizing tumor cell motility. The
increase in exosomal C4.4A corresponds to a pronounced exosome
release under stress [70]. In line with the internalization of membrane
microdomains, such that internalized protein complexes remain in-
tact [71], exosomes collected from CoCl2-treated tumor cells con-
tained C4.4A, α6β4, and MMP14, where, for the latter, clathrin- and
caveolin-dependent internalization has been described [72]. Im-
portantly, the exosomal α6β4- and MMP14-associated C4.4A, but
not soluble C4.4A, supports LN332 degradation. This confirms that
not C4.4A by itself but a complex of C4.4A and α6β4 with proteases
is required for LN fragmentation. Exosomal proteins are functionally
active [73], which also accounts for MMP14 [74]. Accordingly, the
activity of the C4.4A- and α6β4-associated MMP14 is not restricted
to the cell membrane but can additionally prepare the surrounding
of migrating epithelial and tumor cells, thus extending the operational
range of C4.4A.
Conclusions
As summarized in Figure 8, hypoxia-induced C4.4A up-regulation is
accompanied, after a transient increase in LN adhesion, by pronounced
migration, where migration on LN depends on the association of
C4.4A with α6β4 under hypoxia. C4.4A- and α6β4-associated
MMP14 could contribute to the shift toward migration by facilitating
focalized LN degradation. Importantly, hypoxia also strengthens the re-
lease of exosomes, which express C4.4A- and α6β4-associated MMP14.
Exosomes thus expand the range of functional activity of C4.4A in
wound healing, tissue remodeling, and tumor cell spread.
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B5.5 (anti-rα6β4) (not WB) [1]
Anti-hC4.4A [2]
Anti-rpanCD44 (clone Ox50) European Association of Animal Cell
Cultures, Porton Down, United Kingdom
Anti-ruPAR American Diagnostica, Pfungstadt, Germany
Anti-ruPA American Diagnostica, Pfungstadt, Germany
Anti-rMMP2 Dianova, Hamburg, Germany
Anti-rMMP9 Dianova, Hamburg, Germany
Anti-rTACE Stressgen, Ann Arbor, MI
Anti-rMMP14 Santa Cruz Biotech, Heidelberg, Germany
Anti-rHIF-1α Santa Cruz Biotech, Heidelberg, Germany
Anti-rβ4 BD, Heidelberg, Germany
Anti-actin BD, Heidelberg, Germany
Anti-FN BD, Heidelberg, Germany
Anti-rLN111 BD, Heidelberg, Germany
Anti-hLNγ2 (crossr. rat) BD, Heidelberg, Germany
LSα3 (anti-hLNα3 chain) [3]
8A (anti-hLNβ3 chain) [3]
D4B5 (anti-hLNγ2 chain) [3]
Anti-mouse, anti-rabbit, anti-hamster IgG
(HRP-, biotin-, fluorescent dye-labeled)
Dianova, Hamburg, Germany
(B) Matrix Proteins
Fibronectin (Sigma, Munich, Germany) 2 μg/ml
Rat LN111 (Sigma, Munich, Germany) 5 μg/ml
Rat LN332 (804G exosome-depleted
culture supernatant w/o FCS)
50 μg/ml
Human LN332 (A431 exosome-depleted
culture supernatant w/o FCS)
50 μg/ml
(C) Inhibitors
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Table W3. HRE in the C4.4A Promoter.





































Boldface emphasis indicates the start codon; bold blue, HRE1 (−673 bp); bold green, HRE2 (−1183 bp);
bold red, HRE3 (−1557 bp).
